Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Ocugen (OCGN – Research Report), retaining the price target of $4.00.
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight Ocugen’s promising progress and strategic positioning in the biotechnology sector. The company is advancing its modifier gene therapy platform with plans to file three Biologics License Applications (BLAs) over the next three years, targeting retinitis pigmentosa (RP), Stargardt disease (STGD1), and geographic atrophy (GA). This ambitious timeline is supported by Ocugen’s recent achievements, such as FDA alignment for pivotal studies and ongoing clinical trials, which suggest a strong potential for success.
Additionally, Ocugen’s financial position, with sufficient cash reserves to support operations into the first quarter of 2026, provides a stable foundation for executing its strategic plans. The company’s pipeline also includes other promising programs, such as OCU200 for diabetic macular edema, which could offer additional upside potential. These factors collectively contribute to a positive outlook for Ocugen, justifying the Buy rating.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.